دورية أكاديمية
أعرض في EDS

Symptoms of Depression and Anxiety in Adults with High-Grade Glioma: A Literature Review and Findings in a Group of Patients before Chemoradiotherapy and One Year Later.

التفاصيل البيبلوغرافية
العنوان: Symptoms of Depression and Anxiety in Adults with High-Grade Glioma: A Literature Review and Findings in a Group of Patients before Chemoradiotherapy and One Year Later.
المؤلفون: Ribeiro M; Pitié-Salpêtrière-Charles Foix Hospital Group, Neuro-Oncology Departement, Sorbonne University, 75013 Paris, France., Benadjaoud MA; Institute for Radiological Protection and Nuclear Safety, Direction of Human Health, Radiobiology and Regenerative Medicine Research Service, 92260 Fontenay-aux-Roses, France., Moisy L; ICANS-Strasbourg-Europe Cancer Institute, Clinical Research Department, 67200 Strasbourg, France., Jacob J; Pitié-Salpêtrière-Charles Foix Hospital Group, Radiation Oncology Department, Sorbonne University, 75013 Paris, France., Feuvret L; Pitié-Salpêtrière-Charles Foix Hospital Group, Radiation Oncology Department, Sorbonne University, 75013 Paris, France., Balcerac A; CNRS, ENS Paris-Saclay, Centre Borelli, Université Paris-Saclay, 91190 Gif-sur-Yvette, France.; CNRS, Centre Borelli, Université Paris-Cité, 75006 Paris, France.; Neurology Department, Percy Military Training Hospital, 92140 Clamart, France., Bernier MO; Institute for Radiological Protection and Nuclear Safety, Direction of Human Health, Radiobiology and Regenerative Medicine Research Service, 92260 Fontenay-aux-Roses, France., Psimaras D; Pitié-Salpêtrière-Charles Foix Hospital Group, Neuro-Oncology Departement, Sorbonne University, 75013 Paris, France.; OncoNeuroTox Group, Center for Patients with Neurological Complications of Oncologic Treatments, 75013 Paris, France., Hoang-Xuan K; Pitié-Salpêtrière-Charles Foix Hospital Group, Neuro-Oncology Departement, Sorbonne University, 75013 Paris, France., Noel G; ICANS-Strasbourg-Europe Cancer Institute, Radiation Oncology Department, 67200 Strasbourg, France., Jouniaux-Delbez N; Pitié-Salpêtrière-Charles Foix Hospital Group, Neuro-Oncology Departement, Sorbonne University, 75013 Paris, France., Ricard D; CNRS, ENS Paris-Saclay, Centre Borelli, Université Paris-Saclay, 91190 Gif-sur-Yvette, France.; CNRS, Centre Borelli, Université Paris-Cité, 75006 Paris, France.; Neurology Department, Percy Military Training Hospital, 92140 Clamart, France.; OncoNeuroTox Group, Center for Patients with Neurological Complications of Oncologic Treatments, 75013 Paris, France.; French Defense Health Service, Val-de-Grâce Medical School, 75005 Paris, France.
المصدر: Cancers [Cancers (Basel)] 2022 Oct 22; Vol. 14 (21). Date of Electronic Publication: 2022 Oct 22.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: High-grade glioma (HGG) is associated with several external and internal stressors that may induce mood alterations at all stages of the disease. Symptoms of depression and anxiety in persons with glioma have multifactorial etiology and require active follow-up. We reviewed the literature data on the prevalence, mechanisms likely involved in the etiology of mood alterations in persons with HGG and psychosocial interventions found beneficial in treating these symptoms. We also investigated the prevalence and clinical variables that could increase the risk of depression and anxiety symptoms in a group of patients with HGG at two disease time-points: after surgery, before and 1 year after chemoradiotherapy. Literature findings revealed complex mechanisms underlying these symptoms and highlighted the importance of providing early access to palliative care. Our results show a high rate of anxiety and depression symptoms in the first stage of the disease and increased concomitance of these symptoms at the 1-year follow-up. Depression and anxiety symptoms at 1 year after the end of chemoradiotherapy were associated with the presence of symptoms at the first stage of the disease and tumor progression. Antiepileptic drugs and corticosteroid intake did not increase the risk of depressive and anxious symptoms among patients. Active management of mood alterations is an essential part of the care and contributes to patients' well-being and quality of life.
References: Oncotarget. 2015 Oct 13;6(31):30968-74. (PMID: 26427041)
Ann Neurol. 1994 Jul;36(1):48-54. (PMID: 8024261)
J Neurooncol. 2012 Jun;108(2):277-83. (PMID: 22392124)
Int Rev Psychiatry. 2014 Feb;26(1):31-43. (PMID: 24716499)
J Nurs Scholarsh. 2007;39(1):61-7. (PMID: 17393967)
Neurosurgery. 2005 Jun;56(6):1234-41; discussion 1241-2. (PMID: 15918939)
BMJ. 1988 Oct 8;297(6653):897-9. (PMID: 3140969)
J Neurophysiol. 2019 Jan 1;121(1):298-305. (PMID: 30517049)
J Neurooncol. 2020 Sep;149(2):347-356. (PMID: 32909116)
J Clin Oncol. 2012 Apr 10;30(11):1197-205. (PMID: 22412135)
BMJ Open. 2013 Jul 11;3(7):. (PMID: 23847270)
Psychooncology. 2010 Jul;19(7):734-41. (PMID: 19777535)
Prog Neuropsychopharmacol Biol Psychiatry. 2008 Feb 15;32(2):539-43. (PMID: 18031881)
J Neurooncol. 2019 Mar;142(1):183-191. (PMID: 30680509)
J Neurooncol. 2016 Jan;126(1):127-135. (PMID: 26419780)
Psychooncology. 2018 Feb;27(2):607-612. (PMID: 28801927)
Cochrane Database Syst Rev. 2020 Jul 17;7:CD006932. (PMID: 32678464)
Curr Opin Oncol. 2010 Nov;22(6):611-20. (PMID: 20706121)
Neuropsychopharmacology. 2015 Sep;40(10):2368-78. (PMID: 25833129)
World Neurosurg. 2020 Oct;142:e458-e473. (PMID: 32682998)
Lancet Neurol. 2007 May;6(5):421-30. (PMID: 17434097)
J Neurooncol. 2021 May;153(1):89-98. (PMID: 33822293)
Clin Cancer Res. 2013 May 1;19(9):2294-300. (PMID: 23388505)
J Neurooncol. 2018 Dec;140(3):739-748. (PMID: 30471051)
Nat Rev Neurol. 2017 Jan;13(1):52-64. (PMID: 27982041)
Support Care Cancer. 2015 Dec;23(12):3427-35. (PMID: 25761757)
BMC Neurol. 2015 Dec 18;15:261. (PMID: 26684198)
J Psychosom Res. 1999 May;46(5):437-43. (PMID: 10404478)
J Neurosurg Sci. 2012 Sep;56(3):239-45. (PMID: 22854592)
Ann Allergy. 1989 May;62(5):375-91. (PMID: 2655506)
Acta Oncol. 2002;41(4):346-51. (PMID: 12234025)
Lancet. 2012 May 26;379(9830):1984-96. (PMID: 22510398)
Neurosurg Rev. 2020 Apr;43(2):497-511. (PMID: 30094499)
Lancet Psychiatry. 2017 Apr;4(4):330-338. (PMID: 28109647)
Neurosurgery. 2004 Feb;54(2):358-66; discussion 366-7. (PMID: 14744282)
Neuro Oncol. 2017 Nov 6;19(suppl_5):v1-v88. (PMID: 29117289)
Acta Neurochir (Wien). 2018 Jun;160(6):1187-1194. (PMID: 29594548)
Acta Psychiatr Scand. 1983 Jun;67(6):361-70. (PMID: 6880820)
Arch Neurol. 1993 Aug;50(8):873-80. (PMID: 8352676)
Epilepsy Behav. 2017 Nov;76:24-31. (PMID: 28931473)
J Neurooncol. 2009 Sep;94(2):153-61. (PMID: 19262993)
Cancer Biomark. 2014;14(2-3):185-94. (PMID: 24878820)
CNS Oncol. 2015;4(2):71-8. (PMID: 25768331)
Neurosci Biobehav Rev. 2019 Jul;102:371-381. (PMID: 31047891)
CNS Neurosci Ther. 2018 Nov;24(11):994-1003. (PMID: 29508560)
J Neurooncol. 2015 Sep;124(2):185-95. (PMID: 26026860)
Annu Rev Med. 2014;65:203-21. (PMID: 24215332)
Acta Neurol Scand. 2022 Jul;146(1):82-91. (PMID: 35470866)
Transl Psychiatry. 2017 Apr 25;7(4):e1101. (PMID: 28440814)
J Neurooncol. 2007 Sep;84(3):297-304. (PMID: 17594056)
Neuro Oncol. 2013 May;15(5):635-43. (PMID: 23444258)
Nat Rev Immunol. 2016 Jan;16(1):22-34. (PMID: 26711676)
Radiat Res. 2020 May;193(5):407-424. (PMID: 32134362)
PLoS One. 2016 Jul 08;11(7):e0159059. (PMID: 27391954)
Brain Behav Immun. 2020 Jul;87:901-909. (PMID: 32113908)
Eur J Cancer. 2017 Feb;72:46-53. (PMID: 28024266)
JAMA Psychiatry. 2020 Jun 1;77(6):598-606. (PMID: 31995135)
Neural Plast. 2017;2017:6871089. (PMID: 28246558)
J Neurosurg. 2008 Feb;108(2):281-6. (PMID: 18240923)
Mol Cell Endocrinol. 2021 Jan 15;520:111093. (PMID: 33253761)
BMJ Support Palliat Care. 2019 Jun 28;:. (PMID: 31253732)
Surg Neurol. 2009 Mar;71(3):299-303, discussion 303. (PMID: 18786716)
Psychiatry Clin Neurosci. 2009 Oct;63(5):613-22. (PMID: 19788629)
Psychooncology. 2015 May;24(5):540-7. (PMID: 25251838)
Psychooncology. 2014 Feb;23(2):121-30. (PMID: 24105788)
Neurology. 2006 Jan 24;66(2):239-42. (PMID: 16434662)
Cancer Treat Res. 2015;163:171-84. (PMID: 25468232)
J Neurooncol. 2014 Sep;119(3):465-72. (PMID: 25026994)
Neuro Oncol. 2012 Sep;14 Suppl 4:iv3-7. (PMID: 23095828)
Curr Opin Behav Sci. 2019 Aug;28:44-50. (PMID: 31049368)
Neuro Oncol. 2021 Aug 2;23(8):1231-1251. (PMID: 34185076)
Expert Rev Clin Pharmacol. 2011 Mar;4(2):233-42. (PMID: 21666852)
Neuro Oncol. 2012 Apr;14(4):392-404. (PMID: 22307475)
Clin Transl Oncol. 2016 Nov;18(11):1062-1071. (PMID: 26960561)
J Neurosci Nurs. 2011 Feb;43(1):17-28. (PMID: 21338041)
Front Neurol. 2018 Jul 16;9:577. (PMID: 30061860)
Neuropsychiatr Dis Treat. 2015 Apr 22;11:1121-30. (PMID: 25960656)
J Neurosurg Sci. 2015 Dec;59(4):383-92. (PMID: 26375636)
J Clin Oncol. 2010 Apr 10;28(11):1963-72. (PMID: 20231676)
J Natl Cancer Inst. 2012 Jul 3;104(13):990-1004. (PMID: 22767203)
Oncotarget. 2017 Aug 03;8(55):94932-94943. (PMID: 29212279)
Eur J Cancer Care (Engl). 2018 Mar;27(2):e12806. (PMID: 29314470)
Clin Neurol Neurosurg. 2018 Sep;172:8-19. (PMID: 29957299)
N Engl J Med. 2005 Mar 10;352(10):987-96. (PMID: 15758009)
Lancet Oncol. 2017 Jun;18(6):e330-e340. (PMID: 28593859)
Clin Neurol Neurosurg. 2011 Oct;113(8):649-53. (PMID: 21664761)
Ir J Med Sci. 2021 Aug;190(3):1155-1164. (PMID: 33140294)
معلومات مُعتمدة: S.WP13.03.RICARD . Institut du Cerveau
فهرسة مساهمة: Keywords: anxiety; depression; high-grade glioma; palliative care; quality of life
تواريخ الأحداث: Date Created: 20221111 Latest Revision: 20221117
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC9659261
DOI: 10.3390/cancers14215192
PMID: 36358611
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6694
DOI:10.3390/cancers14215192